JP2020522474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522474A5 JP2020522474A5 JP2019565011A JP2019565011A JP2020522474A5 JP 2020522474 A5 JP2020522474 A5 JP 2020522474A5 JP 2019565011 A JP2019565011 A JP 2019565011A JP 2019565011 A JP2019565011 A JP 2019565011A JP 2020522474 A5 JP2020522474 A5 JP 2020522474A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 157
- 239000000427 antigen Substances 0.000 claims description 90
- 102000036639 antigens Human genes 0.000 claims description 90
- 108091007433 antigens Proteins 0.000 claims description 90
- 102000004169 proteins and genes Human genes 0.000 claims description 82
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 16
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 13
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 13
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims description 9
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 9
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 8
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 8
- 102100032530 Glypican-3 Human genes 0.000 claims description 8
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 108030001694 Pappalysin-1 Proteins 0.000 claims description 6
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000037841 lung tumor Diseases 0.000 claims description 3
- 201000008026 nephroblastoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000001608 potassium adipate Substances 0.000 claims description 2
- 239000001601 sodium adipate Substances 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 84
- 239000000203 mixture Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211728A JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510137P | 2017-05-23 | 2017-05-23 | |
| US201762510169P | 2017-05-23 | 2017-05-23 | |
| US201762510168P | 2017-05-23 | 2017-05-23 | |
| US201762510167P | 2017-05-23 | 2017-05-23 | |
| US62/510,168 | 2017-05-23 | ||
| US62/510,169 | 2017-05-23 | ||
| US62/510,167 | 2017-05-23 | ||
| US62/510,137 | 2017-05-23 | ||
| US201762539425P | 2017-07-31 | 2017-07-31 | |
| US62/539,425 | 2017-07-31 | ||
| PCT/US2018/034221 WO2018217945A1 (en) | 2017-05-23 | 2018-05-23 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211728A Division JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522474A JP2020522474A (ja) | 2020-07-30 |
| JP2020522474A5 true JP2020522474A5 (enExample) | 2021-07-26 |
Family
ID=64395873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565011A Pending JP2020522474A (ja) | 2017-05-23 | 2018-05-23 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
| JP2022211728A Pending JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211728A Pending JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200157226A1 (enExample) |
| EP (1) | EP3630181A4 (enExample) |
| JP (2) | JP2020522474A (enExample) |
| KR (1) | KR20200010429A (enExample) |
| CN (1) | CN111278460A (enExample) |
| AU (1) | AU2018273250A1 (enExample) |
| BR (1) | BR112019024620A2 (enExample) |
| CA (1) | CA3064567A1 (enExample) |
| IL (1) | IL270801A (enExample) |
| MX (1) | MX2019013995A (enExample) |
| WO (1) | WO2018217945A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| US20230287081A1 (en) * | 2020-04-16 | 2023-09-14 | Nantong Yichen Biopharma. Co. Ltd. | PD-1 mutant polypeptide and preparation and application thereof |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| MX2024003993A (es) * | 2021-09-29 | 2024-04-25 | Dragonfly Therapeutics Inc | Proteinas que se unen al miembro d del grupo 2 de asesinos naturales (nkg2d), cumulo de diferenciacion 16(cd16) y receptor del factor activador de celulas b (baff-r). |
| WO2023107956A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| EP4561703A1 (en) | 2022-07-29 | 2025-06-04 | Alector LLC | Anti-gpnmb antibodies and methods of use thereof |
| EP4619023A1 (en) | 2022-11-15 | 2025-09-24 | Calico Life Sciences LLC | Anti-papp-a antibodies and methods of use thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AR083705A1 (es) * | 2010-11-04 | 2013-03-13 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX348071B (es) * | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
| US10358492B2 (en) * | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| US20170022291A1 (en) * | 2014-04-01 | 2017-01-26 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| NZ726520A (en) * | 2014-05-29 | 2018-12-21 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| KR102495820B1 (ko) * | 2014-12-19 | 2023-02-06 | 치오메 바이오사이언스 가부시키가이샤 | 5t4 및 cd3에 대한 3개 결합 도메인을 포함하는 융합 단백질 |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| AU2016219785B2 (en) * | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20200048345A1 (en) * | 2015-12-28 | 2020-02-13 | Innate Pharma | Multispecific antigen binding proteins |
| EP3507307A4 (en) * | 2016-09-01 | 2020-04-22 | Immunomab, Inc. | BISPECIFIC ANTIBODIES |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
-
2018
- 2018-05-23 WO PCT/US2018/034221 patent/WO2018217945A1/en not_active Ceased
- 2018-05-23 BR BR112019024620-7A patent/BR112019024620A2/pt not_active Application Discontinuation
- 2018-05-23 EP EP18805878.8A patent/EP3630181A4/en not_active Withdrawn
- 2018-05-23 CN CN201880051761.6A patent/CN111278460A/zh active Pending
- 2018-05-23 AU AU2018273250A patent/AU2018273250A1/en not_active Abandoned
- 2018-05-23 JP JP2019565011A patent/JP2020522474A/ja active Pending
- 2018-05-23 CA CA3064567A patent/CA3064567A1/en active Pending
- 2018-05-23 US US16/615,231 patent/US20200157226A1/en not_active Abandoned
- 2018-05-23 KR KR1020197037753A patent/KR20200010429A/ko not_active Ceased
- 2018-05-23 MX MX2019013995A patent/MX2019013995A/es unknown
-
2019
- 2019-11-20 IL IL270801A patent/IL270801A/en unknown
-
2022
- 2022-12-28 JP JP2022211728A patent/JP2023030174A/ja active Pending